Table 2. Comparison of Imaging Outcome Parameters.
|
Total groups |
Sub-groups |
||||
|---|---|---|---|---|---|
| High-risk N=21 | Low-risk N=16 | p-value | High-risk MZ, N=9 | High-risk DZ, N=12 | |
| Frontolimbic BPP (unitless) | 2.56±0.64 | 2.76±0.48 | 0.32 | 2.86±0.61 | 2.34±0.60 |
| Non-specific binding (unitless) | 1.97±0.53 | 2.10±0.67 | 0.52 | 2.16±0.65 | 1.83±0.39 |
| Cplasma kBq/ml | 1.92±0.51 | 2.02±0.38 | 0.50 | 1.88±0.52 | 1.95±0.52 |
| fp % | 0.31±0.16 | 0.36±0.13 | 0.38 | 0.26±0.15 | 0.35±0.16 |
BPP: binding potential of specific [18F]altanserin binding; Cplasma: steady state activity of non-metabolized [18F]altanserin in plasma; fp: free (non-protein bound) fraction of [18F]altanserin in plasma; MZ: monozygotic; DZ: dizygotic. Non-specific binding is the volume-weighted average partial volume corrected counts per second in the cerebellum gray-matter divided by Cplasma; statistics: for the total high-risk and low-risk groups, differences in numerical variables were tested by unpaired t-tests. Data for the high-risk subgroups are included for descriptive purposes.